Literature DB >> 33025417

miR-4286 is Involved in Connections Between IGF-1 and TGF-β Signaling for the Mesenchymal Transition and Invasion by Glioblastomas.

Kuo-Hao Ho1,2, Peng-Hsu Chen1,2, Chwen-Ming Shih1,2, Yi-Ting Lee1,2, Chia-Hsiung Cheng1,2, Ann-Jeng Liu3, Chin-Cheng Lee4, Ku-Chung Chen5,6.   

Abstract

The insulin-like growth factor (IGF)-1 and transforming growth factor (TGF)-β signal pathways are both recognized as important in regulating cancer prognosis, such as the epithelial-to-mesenchymal transition (EMT) and cell invasion. However, cross-talk between these two signal pathways in glioblastoma multiforme (GBM) is still unclear. In the present study, by analyzing data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GSE) 4412, GBM patients with higher IGF-1 levels exhibited poorer survival. Genes positively correlated with IGF-1 were enriched in EMT and TGF-β signal pathways. IGF-1 treatment enhanced mesenchymal marker expressions and GBM cell invasion. A significant positive correlation was observed for IGF-1 with TGF-β1 (TGFB1) or TGF-β receptor 2 (TGFBR2), both of which participate in TGF-β signaling and are risk genes in the GBM process. IGF-1 stimulation promoted both TGFB1 and TGFBR2 expressions. LY2157299, a TGF-β signaling inhibitor, attenuated IGF-1-enhanced GBM cell invasion and mesenchymal transition. By analyzing IGF-1-regulated microRNA (miR) profiles, miR-4286 was found to be significantly downregulated in IGF-1-treated cells and could be targeted to both TGFB1 and TGFBR2. Overexpression of miR-4286 significantly attenuated expressions of the IGF-1-mediated mesenchymal markers, TGFB1 and TGFBR2. Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-β signaling axis. Finally, our results suggested that miR-4286 might act as a tumor suppressive microRNA in inhibiting IGF-1-enhanced GBM cell invasion. In conclusion, IGF-1 is connected to TGF-β signaling in regulating the mesenchymal transition and cell invasion of GBM through inhibition of miR-4286. Our findings provide new directions and mechanisms for exploring GBM progression.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Epithelial-to-mesenchymal transition (EMT); IGF-1; TGF-β; TGFBR2; miR-4286

Mesh:

Substances:

Year:  2020        PMID: 33025417     DOI: 10.1007/s10571-020-00977-1

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  42 in total

1.  miRWalk2.0: a comprehensive atlas of microRNA-target interactions.

Authors:  Harsh Dweep; Norbert Gretz
Journal:  Nat Methods       Date:  2015-08       Impact factor: 28.547

Review 2.  Cross-talk between IGF-I and TGF-beta signaling pathways.

Authors:  David Danielpour; Kyung Song
Journal:  Cytokine Growth Factor Rev       Date:  2005-11-16       Impact factor: 7.638

3.  Molecular mechanisms of the effect of TGF-β1 on U87 human glioblastoma cells.

Authors:  Igor Bryukhovetskiy; Valeriy Shevchenko
Journal:  Oncol Lett       Date:  2016-06-22       Impact factor: 2.967

4.  The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels.

Authors:  Elisenda Alsina-Sanchis; Agnès Figueras; Álvaro Lahiguera; August Vidal; Oriol Casanovas; Mariona Graupera; Alberto Villanueva; Francesc Viñals
Journal:  Int J Cancer       Date:  2016-06-25       Impact factor: 7.396

5.  Neuron-glia signaling in developing retina mediated by neurotransmitter spillover.

Authors:  Juliana M Rosa; Rémi Bos; Georgeann S Sack; Cécile Fortuny; Amit Agarwal; Dwight E Bergles; John G Flannery; Marla B Feller
Journal:  Elife       Date:  2015-08-14       Impact factor: 8.140

6.  YM500v3: a database for small RNA sequencing in human cancer research.

Authors:  I-Fang Chung; Shing-Jyh Chang; Chen-Yang Chen; Shu-Hsuan Liu; Chia-Yang Li; Chia-Hao Chan; Chuan-Chi Shih; Wei-Chung Cheng
Journal:  Nucleic Acids Res       Date:  2016-11-29       Impact factor: 16.971

7.  Label-Free Quantitative Proteomics in a Methylmalonyl-CoA Mutase-Silenced Neuroblastoma Cell Line.

Authors:  Michele Costanzo; Armando Cevenini; Emanuela Marchese; Esther Imperlini; Maddalena Raia; Luigi Del Vecchio; Marianna Caterino; Margherita Ruoppolo
Journal:  Int J Mol Sci       Date:  2018-11-13       Impact factor: 5.923

8.  IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway.

Authors:  Ku-Chung Chen; Peng-Hsu Chen; Kuo-Hao Ho; Chwen-Ming Shih; Chih-Ming Chou; Chia-Hsiung Cheng; Chin-Cheng Lee
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

9.  SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis.

Authors:  Raul Aguirre-Gamboa; Hugo Gomez-Rueda; Emmanuel Martínez-Ledesma; Antonio Martínez-Torteya; Rafael Chacolla-Huaringa; Alberto Rodriguez-Barrientos; José G Tamez-Peña; Victor Treviño
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

10.  Enhanced Function and Overexpression of Metabotropic Glutamate Receptors 1 and 5 in the Spinal Cord of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis during Disease Progression.

Authors:  Tiziana Bonifacino; Claudia Rebosio; Francesca Provenzano; Carola Torazza; Matilde Balbi; Marco Milanese; Luca Raiteri; Cesare Usai; Ernesto Fedele; Giambattista Bonanno
Journal:  Int J Mol Sci       Date:  2019-09-13       Impact factor: 5.923

View more
  2 in total

Review 1.  MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions.

Authors:  Anja Harder
Journal:  Biomark Res       Date:  2021-04-16

2.  Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer (Review).

Authors:  Rui-Jie Ma; Chao Ma; Kang Hu; Meng-Meng Zhao; Nan Zhang; Zhi-Gang Sun
Journal:  Int J Oncol       Date:  2022-07-20       Impact factor: 5.884

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.